LEXEO THERAPEUTICS INC (LXEO)
US52886X1072 - Common Stock
Taking everything into account, LXEO scores 2 out of 10 in our fundamental rating. LXEO was compared to 565 industry peers in the Biotechnology industry. The financial health of LXEO is average, but there are quite some concerns on its profitability. LXEO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year LXEO has reported negative net income.
In the past year LXEO has reported a negative cash flow from operations.
1.2 Ratios
With a Return On Assets value of -47.49%, LXEO perfoms like the industry average, outperforming 50.45% of the companies in the same industry.
With a decent Return On Equity value of -58.48%, LXEO is doing good in the industry, outperforming 61.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.49% | ||
| ROE | -58.48% | ||
| ROIC | N/A |
ROA(3y)-48.51%
ROA(5y)N/A
ROE(3y)-59.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LXEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
LXEO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, LXEO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.29 indicates that LXEO is not in any danger for bankruptcy at the moment.
LXEO has a better Altman-Z score (3.29) than 73.62% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that LXEO is not too dependend on debt financing.
LXEO's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. LXEO outperforms 44.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.29 |
ROIC/WACCN/A
WACC10.48%
2.3 Liquidity
LXEO has a Current Ratio of 7.21. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LXEO (7.21) is better than 68.63% of its industry peers.
A Quick Ratio of 7.21 indicates that LXEO has no problem at all paying its short term obligations.
LXEO has a Quick ratio of 7.21. This is in the better half of the industry: LXEO outperforms 68.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.21 | ||
| Quick Ratio | 7.21 |
3. Growth
3.1 Past
LXEO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.14%.
Looking at the last year, LXEO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
LXEO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.6%
EPS Next 2Y14.7%
EPS Next 3Y9.02%
EPS Next 5Y6.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
LXEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXEO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.7%
EPS Next 3Y9.02%
5. Dividend
5.1 Amount
No dividends for LXEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LEXEO THERAPEUTICS INC
NASDAQ:LXEO (11/13/2024, 8:00:00 PM)
After market: 7.633 -0.01 (-0.09%)7.64
-0.05 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap252.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.49% | ||
| ROE | -58.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.21 | ||
| Quick Ratio | 7.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y31.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y